CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 150 enrolled
Drug / intervention
ceftaroline +2 moredrug
Likely dose
ceftaroline 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00633152
NCT00633152Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Intramuscular Ceftaroline Versus Intravenous Linezolid in Adult Subjects With Complicated Skin and Skin Structure Infections

Forest Laboratories·interventional·Posted Mar 11, 2008·Updated Mar 14, 2017

In Brief

A Phase 2 clinical trial evaluating ceftaroline, linezolid, and 1 other intervention for Bacterial Infection. Completed, enrolled 150 participants across 13 sites.

Detailed Summary

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin and skin structure infections in adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 11, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.3 years ago

Interventions

ceftarolinedrug

600 mg injected every 12 hours for at least 5 but not more than 14 days

linezoliddrug

600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days

Aztreonamdrug

1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.